The most common and effective treatment for OCD is pharmacological therapy that includes selective serotonin reuptake inhibitors (SSRIs) antidepressants and, in the case of patients resistant to this approach, a combination with antipsychotics. Risperidone and aripiprazole are atypical antipsychotics that act on dopamine (D2) and serotonin receptors. Studies have shown that these drugs are effective in boosting SSRIs for the treatment of OCD in resistant patients.
Currently a high percentage of people diagnosed with OCD do not respond to the existing treatments. Pramipexole is a dopaminergic receptor agonist that specifically binds to dopamine D2 and D3 receptors, having demonstrated benefit in resistant depression.
The aim of this clinical trial is to explore how pramipexole can act in the treatment of OCD in resistant patients, evaluating its safety and efficacy.
Age between 18 and 64 years;
European Portuguese as mother tongue;
Patients diagnosed with OCD, regardless of subtype, according to DSM-5 and/or ICD-10 criteria;
Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score ≥ 16;
Patients with current or anterior history of psychotic illness (schizophrenia, delusions, among others);
Patients with bipolar disorder;
Patients with tick disorder;
Patients with borderline personality disorder;